Search Results
Your search for By Matthew Stenger matches 7176 pages
Showing 951 - 1000Prognostic Performance of a Molecular International Prognostic Scoring System for MDS
In a European study reported in the Journal of Clinical Oncology, Sauta et al found that the recently devised Molecular International Prognostic Scoring System (IPSS-M) had improved prognostic ability vs the standard Revised International Prognostic Scoring System (IPSS-R) in patients with...
Effect of Insurance Status on Racial and Ethnic Inequities in the Diagnosis of Advanced-Stage Cervical Cancer
In a study reported in JAMA Network Open, Holt et al found that health insurance status was a substantial mediator in the diagnosis of advanced-stage vs early-stage cervical cancer across ethnicity and race in patients from the United States. Study Details The retrospective, cross-sectional,...
Extended Performance of an Image-Based Short-Term Risk Model for Predicting Breast Cancer
In a Swedish case-cohort study reported in the Journal of Clinical Oncology, Eriksson et al found that an image-based short-term risk model outperformed a traditional lifestyle/familial risk–based risk model in predicting the likelihood of development of breast cancer over a 10-year period. Study...
How Do Novel Genetic Subtypes of Urothelial Carcinoma Respond to Immune Checkpoint Blockade?
In a study reported in the Journal of Clinical Oncology, Sarfaty et al identified novel genetic subtypes of urothelial carcinoma exhibiting different responses to immune checkpoint blockade. Study Details In the multicenter study, whole-exome sequencing was performed on tumor specimens from 88...
Subcutaneous vs IV Administration of Medications and Fluids in Patients With Cancer: U.S. vs Canadian Cancer Center Methods
In a study reported in a research letter in JAMA Oncology, Tang et al found that the use of the subcutaneous route for administering medications and fluids in patients with cancer was highly predominant in a Canadian center, whereas use of the intravenous (IV) route was nearly universal in a U.S....
Antibiotic Use and Survival Among Patients With Metastatic Pancreatic Cancer Receiving Specific Chemotherapy Regimens
In a retrospective cohort study reported in JAMA Network Open, Fulop et al found that perichemotherapy use of antibiotics was associated with improved survival in patients with metastatic pancreatic ductal adenocarcinoma receiving first-line gemcitabine-based chemotherapy, but not in those...
Lower-Dose Regimens of Exemestane in Postmenopausal Patients With Stage 0 to II ER-Positive Breast Cancer
In a phase IIb trial reported in JAMA Oncology, Serrano et al found that exemestane at 25 mg three times weekly was noninferior to the standard dosing of 25 mg once daily in terms of serum estradiol reduction among postmenopausal patients with stage 0 to II estrogen receptor (ER)-positive breast...
New Prognostic Staging System for De Novo Metastatic Breast Cancer
In a study reported in the Journal of Clinical Oncology, Jennifer K. Plichta, MD, MS, and colleagues formulated a novel prognostic staging system for de novo metastatic breast cancer. Study Details The staging system was developed using data from 42,467 patients from the National Cancer Database...
Change in Frailty Status Among Older Patients Undergoing Locoregional Therapy for Early-Stage Breast Cancer
In a cohort study reported in a research letter in JAMA Surgery, Minami et al found that frailty status worsened in a sizable proportion of older patients receiving locoregional therapy—including lumpectomy or mastectomy—for early-stage breast cancer. Baseline robust status and mastectomy were...
Naporafenib Plus Trametinib in Advanced NRAS-Mutant Melanoma
As reported in the Journal of Clinical Oncology by de Braud et al, findings in the expansion cohort of a phase Ib trial indicate activity with the combination of the BRAF/CRAF kinase inhibitor naporafenib and trametinib in patients with advanced or metastatic NRAS-mutant melanoma. Study Details In ...
Significance of the MGUS-Like Phenotype in Patients With Multiple Myeloma and Light Chain Amyloidosis
In a study reported in the Journal of Clinical Oncology, Burgos et al developed an algorithm to identify patients with multiple myeloma and light-chain amyloidosis who have the monoclonal gammopathy of undetermined significance (MGUS)-like phenotype, as well as identified the association of the...
Poorer Survival in Stage III Colon Cancer With Greater Inflammation After Surgery and Prior to Adjuvant Therapy
In a study reported in JAMA Oncology, En Cheng, MD, PhD, of Kaiser Permanente Northern California, Jeffrey Meyerhardt, MD, MPH, FASCO, of Dana-Farber Cancer Institute, and colleagues found that higher levels of inflammatory biomarkers measured after surgery but before starting chemotherapy were ...
Smoking Cessation Intervention in Patients With a History of Cervical Intraepithelial Neoplasia or Cervical Cancer
In a study reported in the Journal of Clinical Oncology, Vidrine et al found that a smoking cessation intervention was not effective among patients with a history of cervical intraepithelial neoplasia or cervical cancer. Study Details In the trial, 194 evaluable patients who reported current...
First-Line Systemic Treatments in Metastatic Castration-Sensitive Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Oncology, Riaz et al found that first-line triplet therapy in metastatic castration-sensitive prostate cancer did not appear to offer an overall survival advantage vs androgen pathway inhibitor doublet therapy. As stated by the...
DESTINY-Breast03: T-DXd Improves Overall Survival vs T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer
As reported in The Lancet by Sara A. Hurvitz, MD, of the David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival with...
Sotorasib Improves Progression-Free Survival vs Docetaxel in Previously Treated Advanced NSCLC With KRAS G12C Mutation
As reported in The Lancet by Adrianus Johannes de Langen, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, and colleagues, the phase III CodeBreaK200 trial has shown a small but significant improvement in progression-free survival with sotorasib vs docetaxel in previously treated advanced...
Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed...
Regular Approval for Dostarlimab-gxly in dMMR Recurrent or Advanced Endometrial Cancer
On February 9, 2023, dostarlimab-gxly was granted regular approval for adults with mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a U.S. Food and Drug Administration–approved test, whose disease has progressed on or following a prior platinum-containing...
Association of Baseline and Subsequent Cardiovascular Health Metrics to Risk for Incident Cancers
In an analysis from the French GAZEL study reported in JACC: CardioOncology, Thomas Van Sloten, MD, PhD, of the Université Paris Cité, Institut National de la Santé et de la Recherche Médicale, Paris, and colleagues found that better cardiovascular health (CVH) scores at baseline and improvement in ...
Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the...
Adjuvant Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation in Early Breast Cancer: 10 Year Outcomes of Phase III Study
As reported in The Lancet Oncology by Vratislav Strnad, MD, PhD, of University Hospital Erlangen and Comprehensive Cancer Center Erlangen, Germany, and colleagues, 10-year outcomes in a phase III GEC-ESTRO (Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology) trial...
Zanubrutinib Improves Progression-Free Survival vs Ibrutinib in Relapsed or Refractory CLL or SLL
As reported in The New England Journal of Medicine by Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute and Harvard University, and colleagues, the phase III ALPINE trial has shown significantly better progression-free survival with zanubrutinib, a Bruton’s tyrosine kinase (BTK)...
Addition of Vistusertib to Paclitaxel in Platinum-Resistant Ovarian High-Grade Serous Carcinoma
In the UK phase II OCTOPUS study reported in JAMA Oncology, Susana Banerjee, MBBS, MA, PhD, and colleagues found that the addition of the dual mTORC1/mTORC2 inhibitor vistusertib to weekly paclitaxel did not improve progression-free survival among patients with platinum-resistant or -refractory...
Prevalence of HPV DNA and p16INK4a Positivity in Vulvar Cancer and Vulvar Intraepithelial Neoplasia
In a global systematic review and meta-analysis reported in The Lancet Oncology, Li et al found a high prevalence of human papillomavirus (HPV) genotype 16 and HPV33 in vulvar cancer and vulvar intraepithelial neoplasia, as well as a high frequency of p16INK4a positivity in HPV-positive vulvar...
Retroperitoneal Lymph Node Dissection for Early Metastatic Testicular Seminoma
In a phase II trial reported in the Journal of Clinical Oncology, Daneshmand et al found that first-line retroperitoneal lymph node dissection (RPLND) was associated with good outcomes in patients with testicular seminoma with clinically low-volume retroperitoneal lymphadenopathy. As stated by the...
Active Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer: 15-Year Outcomes in the UK ProtecT Trial
As reported in The New England Journal of Medicine by Freddie C. Hamdy, FRCS(Urol), FMedSci, and colleagues, 15-year follow-up of the UK phase III ProtecT trial has shown no significant difference in prostate cancer mortality with active monitoring, surgery, or radiotherapy for patients with...
Laparoscopy-Assisted vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Relapse-Free Survival at 5 Years
As reported in JAMA Surgery by Etoh et al, 5-year follow-up of the Japanese phase II/III JLSSG0901 trial has shown noninferiority in relapse-free survival with laparoscopic-assisted distal gastrectomy vs open distal gastrectomy in patients with locally advanced gastric cancer. Study Details In the...
Pembrolizumab Plus Ifosfamide, Carboplatin, and Etoposide in Relapsed or Refractory Classical Hodgkin Lymphoma
In a phase II trial reported in JAMA Oncology, Locke J. Bryan, MD, and colleagues found that the combination of pembrolizumab with ICE chemotherapy (a regimen including ifosfamide, carboplatin, and etoposide) produced a high rate of complete response in patients with relapsed or refractory...
Low-Dose Tamoxifen to Prevent Recurrence in Patients With Breast Noninvasive Neoplasia: 10-Year Follow-up of TAM-01 Trial
As reported in the Journal of Clinical Oncology by Lazzeroni et al, the 10-year follow-up of the Italian phase III TAM-01 trial has shown that 3 years of low-dose tamoxifen vs placebo continued to be associated with a reduced risk of recurrence of invasive breast cancer or ductal carcinoma in situ...
Axitinib and Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma
In a single-center phase II trial reported in the Journal of Clinical Oncology, Renata Ferrarotto, MD, and colleagues found that the combination of axitinib and avelumab showed evidence of activity in patients with recurrent or metastatic adenoid cystic carcinoma. Study Details In the study, 28...
Detection of Emphysema During Lung Cancer Screening
In an article published in Annals of the American Thoracic Society, James L. Mulshine, MD, and colleagues maintained that the high frequency of emphysema newly identified during low-dose computed tomography (CT) lung cancer screening presents an important opportunity to engage individuals with such ...
Activity of Novel CAR T Cells in Relapsed or Refractory Multiple Myeloma
In a Chinese single-center phase II trial reported in the Journal of Clinical Oncology, Xia et al found that anti–G protein–coupled receptor, class C group 5 member D (GPRC5D) chimeric antigen receptor (CAR) T cells showed activity in patients with relapsed or refractory multiple myeloma. Study...
Addition of Fulvestrant to Alisertib in Endocrine-Resistant Metastatic Breast Cancer
In the phase II TBCRC041 trial reported in JAMA Oncology, Haddad et al found that the addition of fulvestrant to alisertib did not improve objective response rate in postmenopausal patients with HER2-negative, endocrine-resistant metastatic breast cancer. Study Details The multicenter trial,...
AI-Based Model for Nodal Metastasis Detection Using Whole-Slide Images in Bladder Cancer
In a Chinese study reported in The Lancet Oncology, Wu et al found that an artificial intelligence (AI)-based lymph node metastases diagnostic model using whole-slide images performed well in identifying lymph node metastases in patients with bladder cancer, as well as other cancers. Study Details...
Costs of Cancer in Adolescents and Young Adults in the United States
In an analysis by Deloitte Access Economics, commissioned by Teen Cancer America and reported in the Journal of Clinical Oncology, Parsons et al estimated the costs incurred after a cancer diagnosis by adolescents and young adults (AYAs) in the United States. Study Details The objective of the...
Magrolimab Plus Azacitidine in Higher-Risk Myelodysplastic Syndromes
In a phase Ib trial (5F9005) reported in the Journal of Clinical Oncology, David A. Sallman, MD, and colleagues found that the combination of magrolimab and azacitidine showed activity in previously untreated patients with intermediate- to very high–risk myelodysplastic syndromes (MDS). As stated...
Health-Related Quality of Life in the KEYNOTE-826 Trial in Patients With Cervical Cancer
In an analysis from the phase III KEYNOTE-826 trial reported in The Lancet Oncology, Bradley J. Monk, MD, and colleagues found that the addition of pembrolizumab to chemotherapy with or without bevacizumab did not adversely affect health-related quality of life in patients with persistent,...
Regorafenib, Ipilimumab, and Nivolumab in Microsatellite-Stable Metastatic Colorectal Cancer
In a single-institution phase I trial reported in JAMA Oncology, Marwan Fakih, MD, and colleagues found that the combination of regorafenib, ipilimumab, and nivolumab showed evidence of activity in patients with microsatellite-stable metastatic colorectal cancer who did not have liver metastases....
Hyperfractionated vs Standard-Fractionation IMRT in Locally Advanced, Recurrent Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet, You et al found that hyperfractionated vs standard-fractionation intensity-modulated radiotherapy (IMRT) was associated with reduced late severe radiotherapy complications and improved overall survival in patients with locally advanced, recurrent ...
Pelabresib Plus Ruxolitinib in Patients With Myelofibrosis and No Prior JAK Inhibitor Treatment
In the phase II MANIFEST trial, reported in the Journal of Clinical Oncology, John Mascarenhas, MD, and colleagues found that the combination of the bromodomain and extraterminal domain inhibitor pelabresib and ruxolitinib was active in patients with myelofibrosis who had received no prior Janus...
European OnCovid Registry Analysis of COVID-19 Sequelae During Omicron Phase vs Earlier Phases in Patients With Cancer
In an analysis from the European OnCovid registry reported in The Lancet Oncology, Alessio Cortellini, PhD, and colleagues found that rates of COVID-19 sequelae among patients with cancer were lower during the omicron phase of the pandemic vs the alpha-delta and prevaccination phases, consistent...
Impact of Tai Ji Quan or Strength Training vs Stretching in Preventing Falls in Postmenopausal Women Who Received Chemotherapy for Cancer
In the GET FIT study reported in the Journal of Clinical Oncology, Winters-Stone et al found no significant difference in incidence of falls with programs of tai ji quan (also known as tai chi) or strength training vs a stretching control group among postmenopausal women who had received...
Trends in Active Surveillance for Management of Low-Risk Prostate Cancer in the United States
In an analysis reported in JAMA Network Open, Cooperberg et al found that the use of active surveillance (AS) for low-risk prostate cancer in U.S. patients has more than doubled in recent years but remains suboptimal and exhibits wide variations at the urology practice and individual practitioner...
Nirogacestat May Benefit Patients With Desmoid Tumors
As reported in The New England Journal of Medicine by Gounder et al, the phase III DeFi trial has shown significant improvement in progression-free survival with the investigational oral γ-secretase inhibitor nirogacestat vs placebo in patients with desmoid tumors. As noted by the investigators,...
Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer With High FRα Expression
As reported in the Journal of Clinical Oncology by Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, and colleagues, the phase II SORAYA study has shown activity of mirvetuximab soravtansine-gynx, an antibody-drug conjugate targeting folate receptor α (FRα), in women with...
Tucatinib With Trastuzumab in Previously Treated RAS Wild-Type HER2-Positive Advanced Colorectal Cancer
On January 19, 2023, tucatinib was grated accelerated approval for use in combination with trastuzumab for RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.1 Supporting Efficacy...
Omission of Radiotherapy in Children and Adolescents With Early-Stage Classical Hodgkin Lymphoma With Adequate Response to OEPA Chemotherapy
As reported in The Lancet Oncology by Mauz-Körholz et al, children and adolescents with early-stage classical Hodgkin lymphoma enrolled in the EuroNet-PHL-C1 study who had an adequate response to an OEPA chemotherapy regimen (vincristine, etoposide, prednisone, and doxorubicin) and did not receive...
Long-Term Results of European Pediatric Soft-Tissue Sarcoma Study in Nonmetastatic Rhabdomyosarcoma
In an analysis reported in the Journal of Clinical Oncology, Gianni Bisogno, MD, PhD, and colleagues detailed 5-year outcomes among children and adolescents with nonmetastatic rhabdomyosarcoma in the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. Study Details The RMS2005 study...
Sacituzumab Govitecan-hziy in HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
On February 3, 2023, sacituzumab govitecan-hziy was approved for unresectable locally advanced or metastatic hormone receptor (HR)-positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization–negative) breast cancer who have received endocrine-based therapy and at...
Nicotinamide for Chemoprevention of Skin Cancer in Solid Organ Transplant Recipients
In an Australian phase III trial (ONTRANS) reported in The New England Journal of Medicine, Allen et al found that 1 year of treatment with nicotinamide (vitamin B3) vs placebo did not reduce the risk of keratinocyte cancers or actinic keratoses in immunosuppressed solid organ transplant...
